{
    "clinical_study": {
        "@rank": "41969", 
        "arm_group": [
            {
                "arm_group_label": "Injection location1", 
                "arm_group_type": "Experimental", 
                "description": "Single dose IM injection"
            }, 
            {
                "arm_group_label": "Injection location 2", 
                "arm_group_type": "Experimental", 
                "description": "Single dose IM Injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to investigate the pharmacokinetics (PK) of JDP-205\n      injection at 10 mg dose administered by intramuscular injection using various injection\n      techniques in healthy male and female volunteers after a single dose administration."
        }, 
        "brief_title": "A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Acute Urticaria", 
        "condition_browse": {
            "mesh_term": "Urticaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Volunteers meeting all of the following criteria were considered for enrollment in the\n        study:\n\n          1. Male or female volunteer\n\n          2. Volunteer aged of at least 18 years\n\n          3. Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00\n             kg/m2\n\n          4. Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped\n             smoking for at least 12 months before day 1 of this study.\n\n          5. Availability for the entire study period\n\n          6. Motivated volunteer and absence of intellectual problems likely to limit the validity\n             of consent to participate in the study or the compliance with protocol requirements;\n             ability to cooperate adequately; ability to understand and observe the instructions\n             of the physician or designee\n\n          7. Clinical laboratory values within the laboratory's stated normal range; if not within\n             this range, they must be without any clinical significance\n\n          8. Have no clinically significant diseases captured in the medical history or evidence\n             of clinically significant findings on physical examination (including the examination\n             of the anterolateral thigh muscles) and/or clinical laboratory evaluations\n             (hematology, biochemistry, ECG and urinalysis)\n\n          9. Willingness to adhere to the protocol requirements as evidenced by the informed\n             consent form (ICF) duly read, signed and dated by the volunteer\n\n        Exclusion Criteria:\n\n        Volunteers presenting any of the following were not included in the study:\n\n          1. Females who are pregnant or are lactating\n\n          2. Females of childbearing potential who refuse to use an acceptable contraceptive\n             regimen throughout the entire duration of the study (from the screening visit until\n             study completion)\n\n          3. History of significant hypersensitivity to cetirizine or any related products\n             (including excipients of the formulations) as well as severe hypersensitivity\n             reactions (like angioedema) to any drugs\n\n          4. Presence of significant gastrointestinal, liver or kidney disease, or any other\n             conditions known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs or known to potentiate or predispose to undesired effects\n\n          5. History of significant gastrointestinal, liver or kidney disease that may affect drug\n             bioavailability\n\n          6. Presence of significant cardiovascular, pulmonary, hematologic, neurological,\n             psychiatric, endocrine, immunologic or dermatologic disease\n\n          7. Suicidal tendency, history of or disposition to seizures, state of confusion,\n             clinically relevant psychiatric diseases\n\n          8. Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60\n             msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically\n             significant ECG abnormalities\n\n          9. Known presence of rare hereditary problems of galactose and /or lactose intolerance\n\n         10. Maintenance therapy with any drug, or significant history of drug dependency or\n             alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or\n             chronic)\n\n         11. Any clinically significant illness in the previous 28 days before day 1 of this study\n\n         12. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450\n             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin,\n             ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong\n             inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids,\n             phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this\n             study\n\n         13. Use of antihistaminic medication in the previous 7 days before day 1 of this study\n\n         14. Any history of tuberculosis and/or prophylaxis for tuberculosis\n\n         15. Positive urine screening of ethanol and/or drugs of abuse\n\n         16. Positive results to HIV, HBsAg or anti-HCV tests\n\n         17. Females who are pregnant according to a positive serum pregnancy test\n\n         18. Volunteers who took an Investigational Product (in another clinical trial) or donated\n             50 mL or more of blood in the previous 28 days before day 1 of this study\n\n         19. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical\n             studies, etc.) in the previous 56 days before day 1 of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045524", 
            "org_study_id": "ETTAU-01P (CTN-P1-571)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Injection location1", 
                "intervention_name": "Deep muscle injection", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Injection location 2", 
                "intervention_name": "Sub-Q Injection", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec"
                }, 
                "name": "Algorithme Pharma"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Difference in pharmacokinetics: Difference in AUC", 
                "safety_issue": "No", 
                "time_frame": "8 hours post dose"
            }, 
            {
                "measure": "Differences in pharmacokinetics: difference in Cmax", 
                "safety_issue": "No", 
                "time_frame": "8 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "JDP Therapeutics, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Algorithme Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "JDP Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}